• If you are wondering whether Viridian Therapeutics at around US$16.97 is priced for opportunity or risk, the key question is what that tag really says about the business.
• The stock has recently shown sharp moves, with returns of 25.9% over 7 days and 21.6% over 30 days, while year to date it is down 44.7% and up 32.8% over the past year.
• This mix of recent gains and earlier weakness has put valuation back in focus as investors reassess what they are willing to pay for Viridian Therapeutics. Evergreen coverage like this aims to give you a consistent framework to interpret those swings whenever they occur.
• On Simply Wall St’s 6 point valuation checklist the company scores 2 out of 6. The rest of this article will compare what that means across different valuation methods and then finish with a broader way to think about what Viridian Therapeutics might be worth.

Viridian Therapeutics scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Viridian Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and discounting them back to today using a required return. It is essentially asking what those future cash returns are worth in current terms.

For Viridian Therapeutics, the latest twelve month free cash flow (FCF) is a loss of about $305.2 million. Analyst and model projections used here are based on a 2 Stage Free Cash Flow to Equity approach, with specific estimates out to 2030 and then extrapolated numbers beyond that. The projection for 2030 FCF is $540.3 million, with intermediate years moving from losses to positive FCF according to the supplied schedule.

After discounting each of these projected cash flows back to today, the model arrives at an estimated intrinsic value of about $173.25 per share. Against a current share price of roughly $16.97, this implies the stock is considered 90.2% undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Viridian Therapeutics is undervalued by 90.2%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Viridian Therapeutics Price vs Sales

For companies where profits are not yet the main focus, the P/S ratio is often more useful than P/E because it compares what investors are paying to the revenue being generated rather than to earnings that may still be negative.

In general, higher growth expectations and lower perceived risk can justify a higher “normal” P/S multiple, while slower expected growth and higher uncertainty tend to justify a lower one.

Viridian Therapeutics currently trades on a P/S of 24.66x. This compares with the Biotechs industry average P/S of 10.93x and a peer average of 17.25x, so the stock currently sits above both of those reference points.

Simply Wall St’s Fair Ratio is a proprietary estimate of what the P/S multiple might be, given factors such as earnings growth, industry, profit margin, market cap and risks. It goes further than a simple peer or industry comparison by tailoring the multiple to the company’s specific profile instead of assuming that all Biotechs should trade at similar levels.

For Viridian Therapeutics, the Fair Ratio is 0.03x, which is well below the current 24.66x. On this basis, the stock looks expensive relative to its Fair Ratio.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Viridian Therapeutics Narrative

Earlier it was mentioned that there is an even better way to think about valuation. This is where Narratives come in, letting you attach a clear story about Viridian Therapeutics to your own numbers for future revenue, earnings, margins and fair value.

A Narrative is simply your view of what the company is trying to achieve, how the business might develop, and what that could reasonably mean for its financials over time, all linked into one consistent picture.

On Simply Wall St’s Community page, used by millions of investors, Narratives make this process accessible by tying that story to a forecast and then to a Fair Value that you can compare directly with the current price to help decide whether the stock looks attractive or expensive. Those Narratives automatically refresh when fresh news or results are added.

For example, one Viridian Therapeutics Narrative might assume a very optimistic fair value with strong future financials, while another uses much more cautious assumptions and a far lower fair value, showing how different investors can look at the same stock and reach very different conclusions.

Do you think there's more to the story for Viridian Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.